search
Back to results

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

Primary Purpose

Head and Neck Neoplasms

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
paclitaxel albumin-stabilized nanoparticle formulation
Cisplatin
Fluorouracil
Intensity modulated radiation therapy
Cetuximab
Quality-of-life assessment
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Head and Neck Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient must have selected stage III or IVa/b head and neck squamous cell carcinoma (HNSCC); all patients must have T2-T4 primary tumors; (patients with T1 tumors will be excluded); although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligible
  • Patient must have disease at the oropharynx, hypopharynx, larynx, or oral cavity sub-sites
  • Patient must have measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan
  • Patient must be >= 18 years of age.
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2

  • Patient must have adequate bone marrow and organ function as defined below:

    • Absolute neutrophil count (ANC) >= 1500/mcL
    • Platelets > 100,000/mcL
    • Hemoglobin > 9.0 g/dL
    • Total bilirubin =< 1.5 mg/dL
    • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
    • Alkaline phosphatase =< 2.5 x ULN
    • Serum creatinine < 1.8 mg/dL
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
  • Patient must be able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document
  • Patient with uncontrolled diabetes or fasting blood glucose level of greater than 200 mg/dL will be eligible for enrollment but will not be evaluable for PET imaging

Exclusion Criteria:

  • Patient must not have had prior chemotherapy, prior epidermal growth factor receptor (EGFR) targeted therapy, or prior radiation therapy for HNSCC
  • Patient must not have disease at the nasopharyngeal, sinus, or other sub-site not specified in the inclusion criteria; patient must not have unknown primary squamous cell carcinoma of the head and neck
  • Patient must not have a history of prior invasive malignancy diagnosed within 3 years prior to study enrollment other than local stage non-melanoma skin cancer
  • Patient must not be receiving any other investigational agents
  • Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study
  • Patient must not be taking cimetidine or allopurinol. If currently taking either of these medications, patient must discontinue for one week before receiving treatment with nab-paclitaxel
  • Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or serious psychiatric illness/social situations that would limit compliance with study requirements
  • Patient must not be pregnant and/or breastfeeding; a negative serum or urine pregnancy test is required at screening for all female patients of childbearing potential
  • Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study agents; in addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
  • Patient must not have peripheral neuropathy > grade 1

Sites / Locations

  • Washington University School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy

Arm Description

ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks) nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15 Cisplatin 75 mg/m^2 on Day 1 5-FU 750 mg/m^2 on Days 1-3 If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF. Definitive Therapy Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43 Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions. If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks

Outcomes

Primary Outcome Measures

Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site
Response will be assessed by laryngoscopy. CR: disappearance of all lesions

Secondary Outcome Measures

Percentage of Participants With Partial Response (PR) at Primary Tumor Site
Response will be assessed by laryngoscopy. PR: at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter
Number of Participants Per Anatomic Tumor Response by CT Scan
Response assessed using RECIST criteria version 1.0 Complete response: disappearance of all target lesions Partial response: at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter Non-complete response/non-progression: persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal. Progression: at least a 20% increase in the sum of the LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Metabolic Tumor Responses as Measured by FDG-PET/CT
Complete metabolic response (CMR): Complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions Partial metabolic response (PMR): 20% or greater decrease in max SUV from baseline, no metabolic progression of non-target lesions and no new lesions and/or decrease in total number of non-target lesions, no new lesions Stable metabolic disease (SMD) - does not qualify for CMR, PMR, or PMD Progressive metabolic disease (PMD): development of one or more metabolically active lesions or 20% or greater increased in max SUV from baseline, new metabolically active lesions
Overall Survival Rate
-Overall survival rate is the percentage of participants who are alive at 2 years.
Adverse Events as Measured by Number of Participants That Experienced Each Common Adverse Event During ACF Induction Therapy
Assessed by NCI-CTCAE version 3
Changes in Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue
SPARC and Ki-67 expression will be assessed at this institution by IHC stains performed on clinically available tumor specimens (paraffin blocks). The specimens will be collected retrospectively from prior biopsies (pre treatment and following 2 cycles of ACF) that will have consisted of a minimum of two needle cores (16-18 gauge) or two small incisional/excisional pieces of tumor. These will have been placed in 2% buffered formalin and transported to the surgical pathology processing lab.
Complete Response (CR) or Partial Response (PR) at Regional (Neck) Nodes as Measured by Clinical Exam
Changes in Ki-67 Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue
Ki-67 expression will be assessed at this institution by IHC stains performed on clinically available tumor specimens (paraffin blocks). The specimens will be collected retrospectively from prior biopsies (pre treatment and following 2 cycles of ACF) that will have consisted of a minimum of two needle cores (16-18 gauge) or two small incisional/excisional pieces of tumor. These will have been placed in 2% buffered formalin and transported to the surgical pathology processing lab.
Disease-free Survival (DFS) Rate
Progression-free Survival (PFS)
-Progression: at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Total Score
Includes 39 questions: 7 in physical well-being, 6 in emotional well-being, 7 in functional well-being, and 12 in head & neck Scored from 0 (not at all) to 4 (very much) Higher scores indicated worse physical and emotional well-being and better social/family and functional well-being The FACT-H&N Total Score (range 0-148) measures the sum of the physical, social, emotional, functional, and HNCS domains The maximum score of 148 reflects the best quality of life.
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) FACT-G Total Score
Includes 39 questions: 7 in physical well-being, 6 in emotional well-being, 7 in functional well-being, and 12 in head & neck Scored from 0 (not at all) to 4 (very much) Higher scores indicated worse physical and emotional well-being and better social/family and functional well-being The FACT-G Total Score (range 0-108) measures the sum of the physical, social, emotional, and functional domains but excludes the HNCS domain The maximum score of 108 reflects the best quality of life.
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Trial Outcome Index (TOI)
Includes 39 questions: 7 in physical well-being, 6 in emotional well-being, 7 in functional well-being, and 12 in head & neck Scored from 0 (not at all) to 4 (very much) Higher scores indicated worse physical and emotional well-being and better social/family and functional well-being The FACT-H&N TOI (range 0-96) measures the total score for the physical, functional, and HNCS domains but excludes the emotional and social domains The maximum score of 96 reflects the best quality of life.

Full Information

First Posted
March 27, 2012
Last Updated
September 9, 2020
Sponsor
Washington University School of Medicine
Collaborators
Celgene
search

1. Study Identification

Unique Protocol Identification Number
NCT01566435
Brief Title
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
Official Title
Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
August 9, 2012 (Actual)
Primary Completion Date
October 31, 2013 (Actual)
Study Completion Date
October 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
Celgene

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
Detailed Description
Compared to the standard induction regimen of TPF (docetaxel, cisplatin, and 5-FU), the ACCF (nab-paclitaxel, cisplatin, cetuximab, and 5-FU) regimen included two therapeutic changes: nab-paclitaxel was substituted for docetaxel and cetuximab was added. The investigators propose to eliminate cetuximab from the ACCF regimen to isolate the treatment effects of nab-paclitaxel when given with cisplatin and 5-FU. The primary objective of the ACF proposal is to determine the complete (CR) rate by clinical examination at the primary tumor site following two cycles of ACF. An important secondary objective will be to compare the tumor response rates at the primary site following two cycles of ACF to our historical experience following two cycles of ACCF (protocol # ABX 218/HRPO# 08-0911). In addition, the investigators will compare adverse events (AEs) between patients who receive ACF to the historical group given ACCF. From these two comparisons, we aim to determine if either ACF or ACCF is superior based on a balance of efficacy (using the surrogate prognostic endpoint of CR rate at primary tumor site) and toxicity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
Arm Type
Experimental
Arm Description
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks) nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15 Cisplatin 75 mg/m^2 on Day 1 5-FU 750 mg/m^2 on Days 1-3 If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF. Definitive Therapy Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43 Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions. If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
Intervention Type
Drug
Intervention Name(s)
paclitaxel albumin-stabilized nanoparticle formulation
Other Intervention Name(s)
ABI-007, Abraxane, Albumin-Stabilized Nanoparticle Paclitaxel, nab paclitaxel, nab-paclitaxel, nanoparticle
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Other Intervention Name(s)
CACP, CDDP, CPDD, DDP, Neoplatin
Intervention Type
Drug
Intervention Name(s)
Fluorouracil
Other Intervention Name(s)
5-fluorouracil, 5-Fluracil, 5-FU, Adrucil, Efudex, FU
Intervention Type
Radiation
Intervention Name(s)
Intensity modulated radiation therapy
Other Intervention Name(s)
IMRT
Intervention Type
Drug
Intervention Name(s)
Cetuximab
Other Intervention Name(s)
Anti-EGFR Monoclonal Antibody, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225
Intervention Type
Procedure
Intervention Name(s)
Quality-of-life assessment
Other Intervention Name(s)
FACT H&N, FACT/GOG-NTX-4
Intervention Description
ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
Primary Outcome Measure Information:
Title
Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site
Description
Response will be assessed by laryngoscopy. CR: disappearance of all lesions
Time Frame
6 weeks (2 cycles of therapy)
Secondary Outcome Measure Information:
Title
Percentage of Participants With Partial Response (PR) at Primary Tumor Site
Description
Response will be assessed by laryngoscopy. PR: at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter
Time Frame
6 weeks (2 cycles of therapy)
Title
Number of Participants Per Anatomic Tumor Response by CT Scan
Description
Response assessed using RECIST criteria version 1.0 Complete response: disappearance of all target lesions Partial response: at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter Non-complete response/non-progression: persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal. Progression: at least a 20% increase in the sum of the LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time Frame
6 weeks (2 cycles of therapy)
Title
Metabolic Tumor Responses as Measured by FDG-PET/CT
Description
Complete metabolic response (CMR): Complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions Partial metabolic response (PMR): 20% or greater decrease in max SUV from baseline, no metabolic progression of non-target lesions and no new lesions and/or decrease in total number of non-target lesions, no new lesions Stable metabolic disease (SMD) - does not qualify for CMR, PMR, or PMD Progressive metabolic disease (PMD): development of one or more metabolically active lesions or 20% or greater increased in max SUV from baseline, new metabolically active lesions
Time Frame
6 weeks (2 cycles of therapy)
Title
Overall Survival Rate
Description
-Overall survival rate is the percentage of participants who are alive at 2 years.
Time Frame
2 years
Title
Adverse Events as Measured by Number of Participants That Experienced Each Common Adverse Event During ACF Induction Therapy
Description
Assessed by NCI-CTCAE version 3
Time Frame
From start of treatment through 30 days after end of treatment
Title
Changes in Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue
Description
SPARC and Ki-67 expression will be assessed at this institution by IHC stains performed on clinically available tumor specimens (paraffin blocks). The specimens will be collected retrospectively from prior biopsies (pre treatment and following 2 cycles of ACF) that will have consisted of a minimum of two needle cores (16-18 gauge) or two small incisional/excisional pieces of tumor. These will have been placed in 2% buffered formalin and transported to the surgical pathology processing lab.
Time Frame
6 weeks (2 cycles of therapy)
Title
Complete Response (CR) or Partial Response (PR) at Regional (Neck) Nodes as Measured by Clinical Exam
Time Frame
6 weeks (2 cycles of therapy)
Title
Changes in Ki-67 Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue
Description
Ki-67 expression will be assessed at this institution by IHC stains performed on clinically available tumor specimens (paraffin blocks). The specimens will be collected retrospectively from prior biopsies (pre treatment and following 2 cycles of ACF) that will have consisted of a minimum of two needle cores (16-18 gauge) or two small incisional/excisional pieces of tumor. These will have been placed in 2% buffered formalin and transported to the surgical pathology processing lab.
Time Frame
6 weeks (2 cycles of therapy)
Title
Disease-free Survival (DFS) Rate
Time Frame
2 years
Title
Progression-free Survival (PFS)
Description
-Progression: at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time Frame
2 years
Title
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Total Score
Description
Includes 39 questions: 7 in physical well-being, 6 in emotional well-being, 7 in functional well-being, and 12 in head & neck Scored from 0 (not at all) to 4 (very much) Higher scores indicated worse physical and emotional well-being and better social/family and functional well-being The FACT-H&N Total Score (range 0-148) measures the sum of the physical, social, emotional, functional, and HNCS domains The maximum score of 148 reflects the best quality of life.
Time Frame
Through one year after completion of treatment
Title
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) FACT-G Total Score
Description
Includes 39 questions: 7 in physical well-being, 6 in emotional well-being, 7 in functional well-being, and 12 in head & neck Scored from 0 (not at all) to 4 (very much) Higher scores indicated worse physical and emotional well-being and better social/family and functional well-being The FACT-G Total Score (range 0-108) measures the sum of the physical, social, emotional, and functional domains but excludes the HNCS domain The maximum score of 108 reflects the best quality of life.
Time Frame
Through end of chemoradiation
Title
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Trial Outcome Index (TOI)
Description
Includes 39 questions: 7 in physical well-being, 6 in emotional well-being, 7 in functional well-being, and 12 in head & neck Scored from 0 (not at all) to 4 (very much) Higher scores indicated worse physical and emotional well-being and better social/family and functional well-being The FACT-H&N TOI (range 0-96) measures the total score for the physical, functional, and HNCS domains but excludes the emotional and social domains The maximum score of 96 reflects the best quality of life.
Time Frame
Through end of chemoradiation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient must have selected stage III or IVa/b head and neck squamous cell carcinoma (HNSCC); all patients must have T2-T4 primary tumors; (patients with T1 tumors will be excluded); although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligible Patient must have disease at the oropharynx, hypopharynx, larynx, or oral cavity sub-sites Patient must have measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan Patient must be >= 18 years of age. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2 Patient must have adequate bone marrow and organ function as defined below: Absolute neutrophil count (ANC) >= 1500/mcL Platelets > 100,000/mcL Hemoglobin > 9.0 g/dL Total bilirubin =< 1.5 mg/dL Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) Alkaline phosphatase =< 2.5 x ULN Serum creatinine < 1.8 mg/dL Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately Patient must be able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document Patient with uncontrolled diabetes or fasting blood glucose level of greater than 200 mg/dL will be eligible for enrollment but will not be evaluable for PET imaging Exclusion Criteria: Patient must not have had prior chemotherapy, prior epidermal growth factor receptor (EGFR) targeted therapy, or prior radiation therapy for HNSCC Patient must not have disease at the nasopharyngeal, sinus, or other sub-site not specified in the inclusion criteria; patient must not have unknown primary squamous cell carcinoma of the head and neck Patient must not have a history of prior invasive malignancy diagnosed within 3 years prior to study enrollment other than local stage non-melanoma skin cancer Patient must not be receiving any other investigational agents Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study Patient must not be taking cimetidine or allopurinol. If currently taking either of these medications, patient must discontinue for one week before receiving treatment with nab-paclitaxel Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or serious psychiatric illness/social situations that would limit compliance with study requirements Patient must not be pregnant and/or breastfeeding; a negative serum or urine pregnancy test is required at screening for all female patients of childbearing potential Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study agents; in addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated Patient must not have peripheral neuropathy > grade 1
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas Adkins, M.D.
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31147146
Citation
Adkins D, Ley J, Oppelt P, Gay HA, Daly M, Paniello RC, Jackson R, Pipkorn P, Rich J, Zevallos J, Trinkaus K, Thorstad W. Impact on Health-Related Quality of Life of Induction Chemotherapy Compared With Concurrent Cisplatin and Radiation Therapy in Patients With Head and Neck Cancer. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):e123-e131. doi: 10.1016/j.clon.2019.05.007. Epub 2019 May 28.
Results Reference
derived
PubMed Identifier
28797458
Citation
Adkins D, Ley J, Oppelt P, Wildes TM, Gay HA, Daly M, Rich J, Paniello RC, Jackson R, Pipkorn P, Nussenbaum B, Trinkaus K, Thorstad W. nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncol. 2017 Sep;72:26-31. doi: 10.1016/j.oraloncology.2017.07.001. Epub 2017 Jul 8.
Results Reference
derived
Links:
URL
http://www.siteman.wustl.edu
Description
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Learn more about this trial

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

We'll reach out to this number within 24 hrs